PlantPharm BioMed
Technology

Plants as stable genetic carriers

This page consolidates the platform explanation that previously appeared, in slightly different form, across the Home, About, and Market Opportunities pages of the legacy site — one authoritative account of how the technology works.

The PlantPharm production pathway A plant grown as a genetic carrier, its stable biopharmaceutical payload, and the resulting oral solid dose capsule. 01 · Plant-grown carrier 02 · Stable biopharmaceutical 03 · Oral solid dose
Fig. 01 — plant carrier · stable biopharmaceutical payload · oral solid dose capsule
The breakthrough

The world’s first oral solid dose Hepatitis B vaccine

PlantPharm BioMed’s process grew plants with the world’s first oral solid dose Hepatitis B vaccine, which was proven effective in a double-blind, placebo-based, human clinical trial. The ability to grow and deliver vaccines, and other biopharmaceuticals, using plants as the production medium has now become reality.

Solid oral delivery

Replaces hypodermic injection with a pill or pelletized feed dose.

Low-cost & shelf-stable

Easy to ship without cold-chain infrastructure.

Highly scalable

Production scales with plant cultivation rather than industrial bioreactors.

Natural filtration

Removes contaminants such as prions and viroids common to other biopharma manufacturing systems.

Stable replication

Genetically stable propagation eliminates production variability.

Mucosal delivery

Mucosal vaccinations are among the most effective delivery routes available.

Genetic carrier

Built on a patented seed-potato process

PlantPharm’s platform uses genetically stable, pathogen-free seed potatoes as the plant-based carrier for its vaccines. The accelerated-growth process for these seed potatoes was patented worldwide and is the same process currently used in the production of PlantPharm’s Hepatitis B plant-derived vaccine. (Source: Robert G. Britt biography, Meet the Team page.)

The breakthrough

The ability to grow and deliver vaccines, and other biopharmaceuticals, using plants as the production medium has now become reality.
PlantPharm BioMed, Ltd. — Technology overview
Human therapeutic delivery

A platform compatible with hundreds of biopharmaceuticals

Beyond vaccines, PlantPharm’s manufacturing platform technology is deemed compatible with an estimated 500 additional biopharmaceutical drugs, suitable for production as monoclonal antibodies, therapeutic proteins, or peptides.